RxDoctor Payments Data

Calixto Zaldivar, MD

Internal Medicine · Gainesville, FLNPI 1972658292

Payments from drug & device makers

$710in general payments, 2019–2025

Across 9 payments — averaging $78.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alpha Cognition USA, Inc.$166
  • Boehringer Ingelheim$141
  • E.r. Squibb & Sons, L.L.C.$134
  • AbbVie$123
  • Johnson & Johnson$116
  • Sumitomo Pharma America, Inc.$16
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$710100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alpha Cognition USA, Inc.1$166
Boehringer Ingelheim2$141
E.r. Squibb & Sons, L.L.C.2$134
AbbVie1$123
Johnson & Johnson1$116
Sumitomo Pharma America, Inc.1$16
Convatec Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$710 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$280,504
Medicare patients
1,559
Services billed
4,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$64,716
NuplazidPimavanserin Tartrate16$53,973
OzempicSemaglutide27$27,984
FarxigaDapagliflozin Propanediol45$20,043
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog143$17,475
JardianceEmpagliflozin38$14,796
GemtesaVibegron35$14,518
Sevelamer Hcl19$12,308
XareltoRivaroxaban31$11,479
SantylCollagenase Clostridium Hist.20$10,821
TradjentaLinagliptin24$10,814
EntrestoSacubitril/Valsartan29$9,330
NuedextaDextromethorphan Hbr/Quinidine11$8,186
Atorvastatin Calcium405$7,208
Incruse ElliptaUmeclidinium Bromide18$6,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$141$25,61062 claims
Sumitomo Pharma America, Inc.Gemtesa$16$14,51835 claims
Johnson & JohnsonXarelto$116$11,47931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →